John Marshall, MD

Experts discuss their vision for the future of colorectal cancer treatment and anticipated advancements in the field.

The panel of leading oncologists summarize crucial updates and key insights on colorectal cancer from the ASCO 2024 conference.

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Oncology experts evaluate the influence of fruquintinib on current treatment protocols, drawing insights from the FRESCO and FRESCO-2 clinical studies.

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

Key opinion leaders explore treatment selection for third-line metastatic colorectal cancer patients, examining factors influencing therapy choice with particular focus on comparing fruquintinib to TAS-102 (with or without bevacizumab).

The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.

The panel examines prevalent adverse events experienced by patients receiving second-line biomarker-directed therapy for metastatic colorectal cancer.

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Thoughtful discussion of existing and emerging second-line treatment options for patients with metastatic ESCC

Focusing on metastatic ESCC, John Marshall, MD, discusses selecting appropriate first-line treatment strategies for patients.

Shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.

Broad discussion from expert John Marshall, MD, on the current standards of diagnosis care in esophageal squamous cell carcinoma (ESCC).

John L. Marshall, MD, discusses the potential utility of trastuzumab deruxtecan in HER2-positive gastric cancer.

John L. Marshall, MD, discusses early data reported with fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive colorectal cancer from the phase 2 DESTINY-CRC01 trial.

John L. Marshall, MD, discusses the emergence of novel HER2-targeted therapies for patients with colorectal cancer.

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

John L. Marshall, MD, discusses ​sequencing challenges in colorectal cancer.

John L. Marshall, MD, discusses the importance of molecular testing in gastrointestinal cancers.

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.